These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25140364)

  • 21. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years.
    Raghu G
    Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
    Karimi-Shah BA; Chowdhury BA
    N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
    [No Abstract]   [Full Text] [Related]  

  • 23. [Ambroxol].
    Akkoca Yildiz O
    Tuberk Toraks; 2006; 54 Suppl 1():3-14. PubMed ID: 17089236
    [No Abstract]   [Full Text] [Related]  

  • 24. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
    Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M
    Respiration; 2014; 88(3):199-207. PubMed ID: 25115833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?
    Papiris SA; Kagouridis K; Kolilekas L; Triantafillidou C; Tsangaris I; Manali ED
    Eur Respir J; 2012 Sep; 40(3):794-5. PubMed ID: 22941551
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
    Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
    Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
    Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE
    Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic targets in idiopathic pulmonary fibrosis.
    Kolb M; Bonella F; Wollin L
    Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naloxegol oxalate, pirfenidone, and nintedanib.
    Hussar DA; Jeon MM
    J Am Pharm Assoc (2003); 2015; 55(4):461-3. PubMed ID: 26161491
    [No Abstract]   [Full Text] [Related]  

  • 30. Statin strikeout.
    Drazen JM; Gelijns AC
    N Engl J Med; 2014 Jun; 370(23):2240-1. PubMed ID: 24835850
    [No Abstract]   [Full Text] [Related]  

  • 31. [Idiopathic pulmonary fibrosis: A new era, new challenges].
    Cottin V
    Rev Mal Respir; 2014 Sep; 31(7):583-6. PubMed ID: 25239578
    [No Abstract]   [Full Text] [Related]  

  • 32. Idiopathic pulmonary fibrosis and pirfenidone.
    Collard HR
    Eur Respir J; 2010 Apr; 35(4):728-9. PubMed ID: 20356985
    [No Abstract]   [Full Text] [Related]  

  • 33. Benralizumab: for asthma, not yet for COPD.
    Fabbri LM
    Lancet Respir Med; 2014 Nov; 2(11):862-863. PubMed ID: 25306558
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacological therapy does not contribute to survival in idiopathic pulmonary fibrosis.
    Ishii H; Kushima H; Komiya K; Mizunoe S; Kadota J
    Respiration; 2013; 86(1):86-7. PubMed ID: 23594834
    [No Abstract]   [Full Text] [Related]  

  • 35. [Idiopathic pulmonary fibrosis: treatment with pirfenidone].
    Cano-Jiménez E
    Arch Bronconeumol; 2012 Oct; 48 Suppl 2():16-8. PubMed ID: 23630972
    [No Abstract]   [Full Text] [Related]  

  • 36. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
    Hayton C; Chaudhuri N
    Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating idiopathic pulmonary fibrosis: current opportunities and future challenges.
    Richeldi L
    Clin Respir J; 2012 Jul; 6(3):129-30. PubMed ID: 22697263
    [No Abstract]   [Full Text] [Related]  

  • 38. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    George PM; Wells AU
    Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update in diffuse parenchymal lung disease, 2013.
    Rosas IO; Kaminski N
    Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating new treatment options.
    Nathan SD
    Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.